What are umbilical cord MSCs?
Umbilical cord mesenchymal stromal cells, or UC-MSCs, are cells isolated from donated cord tissue and expanded in the laboratory. The tissue can be collected after birth without harvesting marrow or fat from the person who will receive treatment. One donation can supply a bank used to manufacture multiple doses.
Three different things can sit behind the phrase “cord stem cells”: MSCs grown from cord tissue, MSCs isolated from cord blood, and blood-forming cells used in cord-blood transplantation. They are not interchangeable. Cartistem, for example, is a cord-blood-derived MSC product used surgically in the knee; the cord-blood products on FDA’s list serve hematopoietic and immune-system reconstitution. Neither establishes the value of an intravenous cord-tissue MSC infusion for general health. MFDS Cartistem record; FDA product list.
Why are researchers interested?
Cord-derived MSCs can be expanded and banked, making donor-derived treatment possible without a harvesting procedure on the recipient. Laboratory work suggests immune-modulating and signaling effects. Those properties make them candidates for clinical testing; they do not establish that younger donor tissue produces better outcomes than every marrow or fat preparation.
The proposed effects involve interactions with the recipient’s immune system as well as factors released by the cells. They should not be described as a proven system that finds every injury and repairs it. Our MSC overview explains the mechanism and the distinction between a biological hypothesis and a clinical result.
Are any cord-derived MSC products approved?
There are regional approvals, so “investigational everywhere” is inaccurate. In January 2025, China conditionally approved amimestrocel for patients aged 14 and older with steroid-refractory acute graft-versus-host disease predominantly involving the gut. South Korea’s regulator lists Cartistem for specified severe knee-cartilage defects, administered surgically. The products, routes and conditions differ. Chinese announcement; MFDS record.
In the United States, the approved MSC product Ryoncil is derived from bone marrow and is indicated for steroid-refractory acute graft-versus-host disease in children aged two months and older. It is not a cord-cell approval. FDA’s current approved-product list does not contain a cord-tissue MSC product. A product’s status elsewhere does not authorize another clinic’s preparation or another use. Ryoncil label; FDA approved-product list.
What have the controlled trials shown?
Graft-versus-host disease: A 78-person randomized trial tested the cord product PLEB001 alongside second-line treatment. Day-28 response was 60% with cells and 50% with placebo, not a significant difference in the intention-to-treat analysis. The per-protocol analysis and a gut-involvement subgroup favored the cells. Those positive findings deserve attention, but they do not turn the overall primary result into a positive trial. Randomized trial.
A separate pivotal, single-arm study of PLEB001 in 54 patients with gut involvement reported a 63% day-28 response when cells were added to anti-CD25 antibody treatment. It contributes to the product-specific evidence, but without a control arm it cannot isolate the benefit of the cells from the accompanying therapy. Pivotal study.
Knee osteoarthritis: In a small study analyzing 26 participants, two joint injections six months apart produced better results than hyaluronic acid on several pain measures at one year. MRI scores did not differ. In the much larger MILES trial, a different cord-tissue MSC regimen did not outperform corticosteroid injection on the main one-year pain outcomes. These are reasons to keep the exact preparation and comparison in view, rather than declare all cord injections effective or ineffective. Small trial; MILES; MILES correction.
Type 2 diabetes: A double-blind trial randomized 91 adults to three intravenous infusions or placebo. At 48 weeks, 20% of the cell group versus 4.55% of controls met a combined target: HbA1c below 7% and at least a 50% reduction in insulin dose. The study did not show improvement in islet beta-cell function. This is a positive result for a specific combined endpoint, not evidence that diabetes was cured or that everyone could stop insulin. Diabetes trial.
Heart failure: RIMECARD randomized 30 people and found a greater increase in left-ventricular ejection fraction after one infusion at 12 months. It did not establish a reduction in death or heart-failure admissions. The 2026 PRIME-HFrEF trial randomized 40 people to three infusions or placebo and did not improve its primary ejection-fraction outcome. A secondary right-ventricular measure improved, while transient D-dimer increases raised a coagulation question. The studies do not show that one infusion is better than three, because their schedules were not compared head to head. RIMECARD; PRIME-HFrEF.
Severe COVID-19 lung injury: A 24-person randomized trial reported better survival after two infusions, an exploratory finding in a study primarily assessing safety. The 2026 CIRCA-19 report included a separate 22-person randomized comparison using freshly cultured cells. Its main outcome, days free of advanced oxygen or ventilation support, was not significantly improved. Some six-month quality-of-life domains favored treatment among a small number of surviving respondents. Both the promising signals and the uncertainty belong in the account. Early trial; CIRCA-19.
What about frailty, stroke and autism?
A 2024 blinded frailty trial with 30 participants reported better physical quality of life, grip strength and timed mobility after treatment; its five-times sit-to-stand test did not show a significant benefit. A larger 2026 open-label trial randomized 148 older adults, with 147 included after one person withdrew before treatment. Two cord-MSC infusions plus supplements were compared with supplements alone. At nine months, the adjusted difference on the Short Physical Performance Battery was 0.8 points in favor of treatment. Blinded pilot; 2026 trial.
That is a favorable functional result. Participants and treating clinicians knew the allocation, although outcome assessors were blinded, and the trial was conducted at one centre. It does not establish longer life or benefit in healthy younger adults. The published correction clarifies enrollment and baseline percentages; it does not change the reported efficacy or safety conclusions. Frailty correction.
For stroke, one small study randomized 32 people between intravenous and intrathecal delivery and compared them with 16 matched rehabilitation-only controls. It reported improvements in several recovery measures, but the no-cell comparison was not randomized. A separate 156-person trial, UMSIS, is marked completed on ClinicalTrials.gov without posted results as of November 9, 2026. Its planned outcomes cannot be counted as demonstrated benefit. Stroke study; UMSIS registry.
For autism, early open-label cord-tissue MSC work involved 12 children. Six improved on at least two measures, but there was no control group. The later IMPACT trial randomized 137 children. Its posted six-month results show no significant advantage on the primary communication and socialization measure: the estimated difference was 1.32 points, with a confidence interval from -0.88 to 3.51. These are registry-posted results, not a peer-reviewed report of that trial. Early study; IMPACT results.
Does an unrelated donor mean there is no immune risk?
No. Cord MSCs have been used in unrelated recipients, but that does not make them invisible to the immune system. Five of the 12 children in the early autism study developed new antibodies against donor HLA markers. No clinical consequence was identified during the reported follow-up, but that does not settle the implications of later exposure. Pediatric antibody findings.
It is also incorrect to say every cord-MSC trial avoided immune-suppressing drugs. The graft-versus-host disease studies used cells alongside steroids or other immune-directed treatments. The relevant questions are what matching, screening and medication requirements apply to the particular product and patient. Graft-versus-host disease protocol.
What should a product’s documentation show?
Ask for the source tissue, donor screening, manufacturing process, batch identity and release tests. Viability tells you about living cells under the test conditions; potency addresses a relevant biological function. Neither proves that the dose will improve a particular disease.
Not every final cord-MSC dose is thawed from frozen. Some trials used cells thawed from a bank and then cultured again before administration. CIRCA-19 delivered freshly cultured final doses. Other products are thawed for direct use. Documentation should describe the actual process, including any post-thaw testing and the time between preparation and administration. CIRCA-19 manufacturing methods.
These distinctions are explained in our manufacturing guide. A good certificate is valuable product information; clinical evidence is still needed for the proposed treatment.
How reassuring is the safety record?
A 2026 review pooled 42 randomized trials of intravascular cord MSCs in 2,280 adults. Fever was more frequent with treatment. The analysis did not find clear increases in other pooled outcomes such as infection, death, malignancy or thrombotic events. Some included studies followed participants beyond two years, so a blanket one-year ceiling would be wrong. Reporting and follow-up varied, and uncommon or delayed harms remain difficult to exclude. Safety review.
Those findings do not establish safety for children, every manufacturing process, or an intrathecal or joint injection. The 2026 frailty trial reported 12 mild treatment-related events in 10 recipients, including headache, dizziness and chest discomfort, and no serious adverse events. PRIME-HFrEF’s D-dimer finding also illustrates why trial-specific details matter alongside pooled reassurance. Frailty safety results; Heart-failure safety findings.
Encouraging findings
- Some controlled trials report improvements in symptoms, function or disease response.
- Donor-derived manufacturing can avoid a harvesting procedure on the recipient.
- There are defined regional approvals for particular cord-derived products.
Important limits
- Several trials missed their main endpoint, including IMPACT and PRIME-HFrEF.
- Small studies and subgroup findings need confirmation.
- Evidence from one route or product does not establish another’s safety or benefit.
Useful questions
- Which exact product was tested for this condition?
- What is the local authorization or trial pathway?
- What follow-up will measure benefit, lack of benefit and adverse effects?
Questions people ask
Are umbilical cord MSCs approved?
Some specific products have regional approvals. China conditionally approved amimestrocel for a defined steroid-refractory acute graft-versus-host disease population. South Korea lists Cartistem, a cord-blood-derived MSC product for specified severe knee-cartilage defects. These do not authorize other cord preparations or uses. The US-approved MSC product Ryoncil is bone-marrow-derived. Chinese announcement; MFDS record; Ryoncil label.
Does the donor need to match me?
Unrelated donor cells have been used in trials, but matching and treatment requirements depend on the product and protocol. MSCs can provoke immune recognition: an early pediatric study found new donor-directed antibodies in five of 12 recipients. Graft-versus-host disease studies also used immune-suppressing treatments, so “no matching and no immune drugs” is not a universal rule. Antibody study; Graft-versus-host disease trial.
Are all cord MSC doses frozen before treatment?
No. Some final doses are thawed for use; others are freshly cultured, sometimes after recovery from a frozen cell bank. CIRCA-19 used freshly cultured final doses. Ask how the actual preparation was handled and which release tests were performed. CIRCA-19 methods.
Does the safety review prove these treatments are safe?
No single review can establish that for every patient and product. The adult intravascular-trial review found increased fever and no clear increase in the other pooled safety outcomes. It does not settle rare or delayed harms, pediatric use or other delivery routes. Safety review.
The evidence
Selected original studies, registry records and regulatory sources checked November 9, 2026. Study design and access limits are reflected in the discussion above. Explore related records on our Science page.
This article is for educational purposes only and is not medical advice, a diagnosis, or a treatment recommendation. Evidence and approvals apply to the products and populations described. Any treatment decision should be made with a qualified physician. Individual results vary.